BlueStone Venture Partners

Based in the Boston biotech and medtech hub, Elucid Bioimaging is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, vascuCAP, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.

Akadeum Life Sciences, Inc. is a life sciences company headquartered in Ann Arbor, Michigan, that specializes in manufacturing microbubble cell separation products. Founded in 2014, the company focuses on isolating mammalian and bacterial cells from complex mixtures, offering a range of products including T cell and B cell isolation kits for human and mouse cells. Additionally, Akadeum provides depletion microbubbles for red blood cell removal and streptavidin microbubbles for targeting and capturing various biological entities. Its innovative approach utilizes buoyancy-activated cell sorting, which employs microscopic microbubbles to effectively isolate target cells by floating them to the surface of liquid samples. These advancements enable medical practitioners to perform downstream testing and analysis with enhanced efficiency. The company sells its products online and has established a strategic partnership with Agilent Technologies.

Based in the Boston biotech and medtech hub, Elucid Bioimaging is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, vascuCAP, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.

GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, focused on enhancing the treatment options for patients with brain tumors. Founded in 2017, the company has developed GammaTile, an innovative medical device that integrates a biocompatible collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a conformable and bioresorbable solution that can potentially prevent disease progression and improve patient quality of life. GammaTile has received multiple patents and has shown promise in clinical trials, with significant improvements observed in patients treated at the Barrow Neurological Institute. This approach aims to revolutionize care for the estimated 176,000 individuals diagnosed with brain tumors annually in the United States.

Pyx Health, Inc. is a healthcare IT company focused on reducing loneliness and social isolation through its innovative mobile solution. Established in 2017 and headquartered in Tucson, Arizona, the company connects members outside of traditional care settings, providing critical support during vulnerable moments, particularly after transitions of care. Pyx Health’s platform includes Pyxir, a chatbot designed to accompany members throughout their healthcare journey. This engaging chatbot fosters healthy interactions and builds trusted companionship, offering assistance and timely interventions while addressing social determinants of health. Through a blend of artificial intelligence and human interventions, Pyx Health aims to enhance the overall well-being of its users.

Paradigm Diagnostics specializes in advanced cancer diagnostics and biomarker-driven clinical trials, aiming to enhance treatment options for cancer patients. Utilizing next-generation sequencing and comprehensive biomarker analysis, Paradigm assesses the genomic and proteomic characteristics of individual tumors. This information allows for a detailed understanding of the specific cancer pathways involved and the potential therapies tailored to each patient's unique tumor profile. By focusing on personalized medicine, Paradigm empowers healthcare providers to offer targeted treatment strategies, ultimately improving patient outcomes in cancer care.

GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, focused on enhancing the treatment options for patients with brain tumors. Founded in 2017, the company has developed GammaTile, an innovative medical device that integrates a biocompatible collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a conformable and bioresorbable solution that can potentially prevent disease progression and improve patient quality of life. GammaTile has received multiple patents and has shown promise in clinical trials, with significant improvements observed in patients treated at the Barrow Neurological Institute. This approach aims to revolutionize care for the estimated 176,000 individuals diagnosed with brain tumors annually in the United States.

BroadSpot Imaging Corporation focuses on developing diagnostic medical devices for eye care, specifically in the area of retinal imaging. The company employs advanced imaging technologies and compact, cloud-connected electronics to create cost-effective handheld instruments that replace traditional bulky and expensive diagnostic tools. By integrating AI and machine learning applications, BroadSpot Imaging aims to enhance the efficiency and accessibility of eye care services. Their innovations are designed to meet the growing demand for high-quality diagnostics, particularly as the population ages, allowing eye care professionals to serve more patients effectively and affordably across various medical settings.